cd5 antibody Search Results


anti cd5  (R&D Systems)
90
R&D Systems anti cd5
Anti Cd5, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd5/product/R&D Systems
Average 90 stars, based on 1 article reviews
anti cd5 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
t lymphocytes  (Bioss)
92
Bioss t lymphocytes
Quantitative comparison of the number of positive cells per field for (A) macrophages (CD68) and (B) <t>T</t> <t>lymphocytes</t> <t>(CD5)</t> showing significant differences for the BMSCs + ASC group compared with the ASC group (*P<0.05) and control group ( # P<0.05) at 2 weeks after surgery. (C) IgM shows no significant difference (P>0.05) among the groups. ASC, acellular spinal cord; BMSCs, bone marrow stromal cells; IgM, immunoglobulin M.
T Lymphocytes, supplied by Bioss, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/t lymphocytes/product/Bioss
Average 92 stars, based on 1 article reviews
t lymphocytes - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
lgr5 rabbit polyclonal igg  (OriGene)
92
OriGene lgr5 rabbit polyclonal igg
Sequences of primer pairs (sense and antisense, respectively) used for amplifying the genes of interest (GOI) and the internal reference gene (GAPDH) used for their nor Primer designed by the PROBEFINDER software ( https://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp ).
Lgr5 Rabbit Polyclonal Igg, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lgr5 rabbit polyclonal igg/product/OriGene
Average 92 stars, based on 1 article reviews
lgr5 rabbit polyclonal igg - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
cd5  (Proteintech)
92
Proteintech cd5
Figure 2. Dynamic alterations of lung TJ and AJ, HUVEC permeability, and neutrophils after LPS administration in vivo and in vitro. E-cadherin (A, A9), VE-cadherin (B, B9), occludin (C, C0), CD11b (E, E9), and MPO (F, F9) staining and quantification of relative intensity or positive cells in 1 alveoli at 1, 3, 5, and 7 d after administration of LPS (15 mg/kg) or saline; and CD3, <t>CD5,</t> CD19, and CD45 staining (G) at 3 d after LPS treatment are shown. D) Double-labeling images are shown of occludin (red) with E-cadherin or VE-cadherin (green) and superimposition with DAPI (blue). H) Percentage of CD11b-, MPO-, CD3-, CD5-, CD19-, and CD45-positive cells in 1 alveoli. I) Levels of IL-6, IL-8, and TNF-a and MPO activity in the supernatants of human neutrophils at 1, 3, 5, 7, and 9 h after LPS (10 mg/ml) treatment are shown. J) HUVEC monolayer permeability, as reflected by FITC-albumin fluorescence intensity, was analyzed at 1, 3, 5, 7, and 9 h after treatment of LPS alone or LPS + neutrophil supernatants (LPS + S). Values are expressed as the means 6 SE; n = 3 (I, J); n = 10–13 alveoli from 3 mice (A2C9, E9,F9, H). Scale bars: 5 mm (D); 30 mm (A–C. E–G). N.S., no significant difference. **P , 0.01 compared with the control group, ##P , 0.01 compared with LPS group at 1 h.
Cd5, supplied by Proteintech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd5/product/Proteintech
Average 92 stars, based on 1 article reviews
cd5 - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
cd5 pe vio770 miltenyi biotec 130 111 109 rea782  (Miltenyi Biotec)
94
Miltenyi Biotec cd5 pe vio770 miltenyi biotec 130 111 109 rea782
Figure 2. Dynamic alterations of lung TJ and AJ, HUVEC permeability, and neutrophils after LPS administration in vivo and in vitro. E-cadherin (A, A9), VE-cadherin (B, B9), occludin (C, C0), CD11b (E, E9), and MPO (F, F9) staining and quantification of relative intensity or positive cells in 1 alveoli at 1, 3, 5, and 7 d after administration of LPS (15 mg/kg) or saline; and CD3, <t>CD5,</t> CD19, and CD45 staining (G) at 3 d after LPS treatment are shown. D) Double-labeling images are shown of occludin (red) with E-cadherin or VE-cadherin (green) and superimposition with DAPI (blue). H) Percentage of CD11b-, MPO-, CD3-, CD5-, CD19-, and CD45-positive cells in 1 alveoli. I) Levels of IL-6, IL-8, and TNF-a and MPO activity in the supernatants of human neutrophils at 1, 3, 5, 7, and 9 h after LPS (10 mg/ml) treatment are shown. J) HUVEC monolayer permeability, as reflected by FITC-albumin fluorescence intensity, was analyzed at 1, 3, 5, 7, and 9 h after treatment of LPS alone or LPS + neutrophil supernatants (LPS + S). Values are expressed as the means 6 SE; n = 3 (I, J); n = 10–13 alveoli from 3 mice (A2C9, E9,F9, H). Scale bars: 5 mm (D); 30 mm (A–C. E–G). N.S., no significant difference. **P , 0.01 compared with the control group, ##P , 0.01 compared with LPS group at 1 h.
Cd5 Pe Vio770 Miltenyi Biotec 130 111 109 Rea782, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd5 pe vio770 miltenyi biotec 130 111 109 rea782/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
cd5 pe vio770 miltenyi biotec 130 111 109 rea782 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
cd5  (Miltenyi Biotec)
94
Miltenyi Biotec cd5
Figure 2. Dynamic alterations of lung TJ and AJ, HUVEC permeability, and neutrophils after LPS administration in vivo and in vitro. E-cadherin (A, A9), VE-cadherin (B, B9), occludin (C, C0), CD11b (E, E9), and MPO (F, F9) staining and quantification of relative intensity or positive cells in 1 alveoli at 1, 3, 5, and 7 d after administration of LPS (15 mg/kg) or saline; and CD3, <t>CD5,</t> CD19, and CD45 staining (G) at 3 d after LPS treatment are shown. D) Double-labeling images are shown of occludin (red) with E-cadherin or VE-cadherin (green) and superimposition with DAPI (blue). H) Percentage of CD11b-, MPO-, CD3-, CD5-, CD19-, and CD45-positive cells in 1 alveoli. I) Levels of IL-6, IL-8, and TNF-a and MPO activity in the supernatants of human neutrophils at 1, 3, 5, 7, and 9 h after LPS (10 mg/ml) treatment are shown. J) HUVEC monolayer permeability, as reflected by FITC-albumin fluorescence intensity, was analyzed at 1, 3, 5, 7, and 9 h after treatment of LPS alone or LPS + neutrophil supernatants (LPS + S). Values are expressed as the means 6 SE; n = 3 (I, J); n = 10–13 alveoli from 3 mice (A2C9, E9,F9, H). Scale bars: 5 mm (D); 30 mm (A–C. E–G). N.S., no significant difference. **P , 0.01 compared with the control group, ##P , 0.01 compared with LPS group at 1 h.
Cd5, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd5/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
cd5 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
anti cd5  (Novus Biologicals)
93
Novus Biologicals anti cd5
Figure 2. Dynamic alterations of lung TJ and AJ, HUVEC permeability, and neutrophils after LPS administration in vivo and in vitro. E-cadherin (A, A9), VE-cadherin (B, B9), occludin (C, C0), CD11b (E, E9), and MPO (F, F9) staining and quantification of relative intensity or positive cells in 1 alveoli at 1, 3, 5, and 7 d after administration of LPS (15 mg/kg) or saline; and CD3, <t>CD5,</t> CD19, and CD45 staining (G) at 3 d after LPS treatment are shown. D) Double-labeling images are shown of occludin (red) with E-cadherin or VE-cadherin (green) and superimposition with DAPI (blue). H) Percentage of CD11b-, MPO-, CD3-, CD5-, CD19-, and CD45-positive cells in 1 alveoli. I) Levels of IL-6, IL-8, and TNF-a and MPO activity in the supernatants of human neutrophils at 1, 3, 5, 7, and 9 h after LPS (10 mg/ml) treatment are shown. J) HUVEC monolayer permeability, as reflected by FITC-albumin fluorescence intensity, was analyzed at 1, 3, 5, 7, and 9 h after treatment of LPS alone or LPS + neutrophil supernatants (LPS + S). Values are expressed as the means 6 SE; n = 3 (I, J); n = 10–13 alveoli from 3 mice (A2C9, E9,F9, H). Scale bars: 5 mm (D); 30 mm (A–C. E–G). N.S., no significant difference. **P , 0.01 compared with the control group, ##P , 0.01 compared with LPS group at 1 h.
Anti Cd5, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd5/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
anti cd5 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
antigens cd5  (Miltenyi Biotec)
94
Miltenyi Biotec antigens cd5
Figure 2. Dynamic alterations of lung TJ and AJ, HUVEC permeability, and neutrophils after LPS administration in vivo and in vitro. E-cadherin (A, A9), VE-cadherin (B, B9), occludin (C, C0), CD11b (E, E9), and MPO (F, F9) staining and quantification of relative intensity or positive cells in 1 alveoli at 1, 3, 5, and 7 d after administration of LPS (15 mg/kg) or saline; and CD3, <t>CD5,</t> CD19, and CD45 staining (G) at 3 d after LPS treatment are shown. D) Double-labeling images are shown of occludin (red) with E-cadherin or VE-cadherin (green) and superimposition with DAPI (blue). H) Percentage of CD11b-, MPO-, CD3-, CD5-, CD19-, and CD45-positive cells in 1 alveoli. I) Levels of IL-6, IL-8, and TNF-a and MPO activity in the supernatants of human neutrophils at 1, 3, 5, 7, and 9 h after LPS (10 mg/ml) treatment are shown. J) HUVEC monolayer permeability, as reflected by FITC-albumin fluorescence intensity, was analyzed at 1, 3, 5, 7, and 9 h after treatment of LPS alone or LPS + neutrophil supernatants (LPS + S). Values are expressed as the means 6 SE; n = 3 (I, J); n = 10–13 alveoli from 3 mice (A2C9, E9,F9, H). Scale bars: 5 mm (D); 30 mm (A–C. E–G). N.S., no significant difference. **P , 0.01 compared with the control group, ##P , 0.01 compared with LPS group at 1 h.
Antigens Cd5, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antigens cd5/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
antigens cd5 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
anti cd5 apc  (Miltenyi Biotec)
94
Miltenyi Biotec anti cd5 apc
Figure 2. Dynamic alterations of lung TJ and AJ, HUVEC permeability, and neutrophils after LPS administration in vivo and in vitro. E-cadherin (A, A9), VE-cadherin (B, B9), occludin (C, C0), CD11b (E, E9), and MPO (F, F9) staining and quantification of relative intensity or positive cells in 1 alveoli at 1, 3, 5, and 7 d after administration of LPS (15 mg/kg) or saline; and CD3, <t>CD5,</t> CD19, and CD45 staining (G) at 3 d after LPS treatment are shown. D) Double-labeling images are shown of occludin (red) with E-cadherin or VE-cadherin (green) and superimposition with DAPI (blue). H) Percentage of CD11b-, MPO-, CD3-, CD5-, CD19-, and CD45-positive cells in 1 alveoli. I) Levels of IL-6, IL-8, and TNF-a and MPO activity in the supernatants of human neutrophils at 1, 3, 5, 7, and 9 h after LPS (10 mg/ml) treatment are shown. J) HUVEC monolayer permeability, as reflected by FITC-albumin fluorescence intensity, was analyzed at 1, 3, 5, 7, and 9 h after treatment of LPS alone or LPS + neutrophil supernatants (LPS + S). Values are expressed as the means 6 SE; n = 3 (I, J); n = 10–13 alveoli from 3 mice (A2C9, E9,F9, H). Scale bars: 5 mm (D); 30 mm (A–C. E–G). N.S., no significant difference. **P , 0.01 compared with the control group, ##P , 0.01 compared with LPS group at 1 h.
Anti Cd5 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd5 apc/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
anti cd5 apc - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
biotin antibody cocktail  (Miltenyi Biotec)
94
Miltenyi Biotec biotin antibody cocktail
Figure 2. Dynamic alterations of lung TJ and AJ, HUVEC permeability, and neutrophils after LPS administration in vivo and in vitro. E-cadherin (A, A9), VE-cadherin (B, B9), occludin (C, C0), CD11b (E, E9), and MPO (F, F9) staining and quantification of relative intensity or positive cells in 1 alveoli at 1, 3, 5, and 7 d after administration of LPS (15 mg/kg) or saline; and CD3, <t>CD5,</t> CD19, and CD45 staining (G) at 3 d after LPS treatment are shown. D) Double-labeling images are shown of occludin (red) with E-cadherin or VE-cadherin (green) and superimposition with DAPI (blue). H) Percentage of CD11b-, MPO-, CD3-, CD5-, CD19-, and CD45-positive cells in 1 alveoli. I) Levels of IL-6, IL-8, and TNF-a and MPO activity in the supernatants of human neutrophils at 1, 3, 5, 7, and 9 h after LPS (10 mg/ml) treatment are shown. J) HUVEC monolayer permeability, as reflected by FITC-albumin fluorescence intensity, was analyzed at 1, 3, 5, 7, and 9 h after treatment of LPS alone or LPS + neutrophil supernatants (LPS + S). Values are expressed as the means 6 SE; n = 3 (I, J); n = 10–13 alveoli from 3 mice (A2C9, E9,F9, H). Scale bars: 5 mm (D); 30 mm (A–C. E–G). N.S., no significant difference. **P , 0.01 compared with the control group, ##P , 0.01 compared with LPS group at 1 h.
Biotin Antibody Cocktail, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotin antibody cocktail/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
biotin antibody cocktail - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
igg1 pe cd7 miltenyi biotec  (Miltenyi Biotec)
94
Miltenyi Biotec igg1 pe cd7 miltenyi biotec
Figure 2. Dynamic alterations of lung TJ and AJ, HUVEC permeability, and neutrophils after LPS administration in vivo and in vitro. E-cadherin (A, A9), VE-cadherin (B, B9), occludin (C, C0), CD11b (E, E9), and MPO (F, F9) staining and quantification of relative intensity or positive cells in 1 alveoli at 1, 3, 5, and 7 d after administration of LPS (15 mg/kg) or saline; and CD3, <t>CD5,</t> CD19, and CD45 staining (G) at 3 d after LPS treatment are shown. D) Double-labeling images are shown of occludin (red) with E-cadherin or VE-cadherin (green) and superimposition with DAPI (blue). H) Percentage of CD11b-, MPO-, CD3-, CD5-, CD19-, and CD45-positive cells in 1 alveoli. I) Levels of IL-6, IL-8, and TNF-a and MPO activity in the supernatants of human neutrophils at 1, 3, 5, 7, and 9 h after LPS (10 mg/ml) treatment are shown. J) HUVEC monolayer permeability, as reflected by FITC-albumin fluorescence intensity, was analyzed at 1, 3, 5, 7, and 9 h after treatment of LPS alone or LPS + neutrophil supernatants (LPS + S). Values are expressed as the means 6 SE; n = 3 (I, J); n = 10–13 alveoli from 3 mice (A2C9, E9,F9, H). Scale bars: 5 mm (D); 30 mm (A–C. E–G). N.S., no significant difference. **P , 0.01 compared with the control group, ##P , 0.01 compared with LPS group at 1 h.
Igg1 Pe Cd7 Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/igg1 pe cd7 miltenyi biotec/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
igg1 pe cd7 miltenyi biotec - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

Image Search Results


Quantitative comparison of the number of positive cells per field for (A) macrophages (CD68) and (B) T lymphocytes (CD5) showing significant differences for the BMSCs + ASC group compared with the ASC group (*P<0.05) and control group ( # P<0.05) at 2 weeks after surgery. (C) IgM shows no significant difference (P>0.05) among the groups. ASC, acellular spinal cord; BMSCs, bone marrow stromal cells; IgM, immunoglobulin M.

Journal: Experimental and Therapeutic Medicine

Article Title: Reduced inflammatory cell recruitment and tissue damage in spinal cord injury by acellular spinal cord scaffold seeded with mesenchymal stem cells

doi: 10.3892/etm.2016.3941

Figure Lengend Snippet: Quantitative comparison of the number of positive cells per field for (A) macrophages (CD68) and (B) T lymphocytes (CD5) showing significant differences for the BMSCs + ASC group compared with the ASC group (*P<0.05) and control group ( # P<0.05) at 2 weeks after surgery. (C) IgM shows no significant difference (P>0.05) among the groups. ASC, acellular spinal cord; BMSCs, bone marrow stromal cells; IgM, immunoglobulin M.

Article Snippet: Fluorescein isothiocyanate-labeled primary antibodies against immunoglobulin M (FITC anti-rat IgM; dilution, 1:100; cat. no. RUO 400801; BioLegend, Inc., San Diego, CA, USA), macrophages (anti-CD68/FITC; 100 µg; dilution, 1:100; cat. no. BS-0649R; Bioss, Inc., Woburn, MA, USA), and T lymphocytes (anti-CD5/FITC; dilution, 1:100; cat. no. BS-10218R; Bioss, Inc.) were used to evaluate each section.

Techniques:

Sequences of primer pairs (sense and antisense, respectively) used for amplifying the genes of interest (GOI) and the internal reference gene (GAPDH) used for their nor Primer designed by the PROBEFINDER software ( https://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp ).

Journal: PLoS ONE

Article Title: Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures

doi: 10.1371/journal.pone.0142124

Figure Lengend Snippet: Sequences of primer pairs (sense and antisense, respectively) used for amplifying the genes of interest (GOI) and the internal reference gene (GAPDH) used for their nor Primer designed by the PROBEFINDER software ( https://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp ).

Article Snippet: Cells were rinsed twice with PBS buffer for 2 min, blocked and incubated 1 hour with the following antibodies: Vimentin mouse monoclonal IgG1 (sc-32322, Santa Cruz Biotechnology), α-SMA mouse monoclonal IgG1(M0851, Dako), E-Cadherin mouse monoclonal IgG1 (sc-21791, Santa Cruz Biotechnology), CD326/EpCAM mouse monoclonal IgG1 (sc-59782, Santa Cruz Biotechnology), CD133/PROM1 mouse monoclonal IgG1 (TA309943, Origene), LGR5 rabbit polyclonal IgG (TA301323,Origene), cytokeratin-19 (CK-19) sc-6278 CK-19 mouse monoclonal IgG2a (Santa Cruz Biotechnology), Interleukin 6 (IL6) mouse monoclonal IgG2a (ab9324, Abcam) at room temperature.

Techniques: Software, Amplification

(A) Immunohistochemical and immunofluorescence analyses of mixed- and mucin-IHCCA primary cultures for Vimentin, α-SMA, E-Cadherin and the “epithelial” cancer stem cell markers CD133+, EpCAM+, LGR5+ and for IL6. A diffuse positivity for mesenchymal markers (Vimentin, α-SMA) and IL6 was observed while E-Cadherin was virtually negative and less than 5% cells where positive for the “epithelial” cancer stem cell markers. Representative experiment of N = 12 independent staining performed in separate primary cultures. (B) Flow cytometry analyses of primary cultures of mixed- and mucin-IHCCA (20–30 passages), labeled with anti-CD13, anti-CD90, anti-EpCAM, anti-CD133, and anti-LGR5 antibodies. Bar graphs and representative plots. Cells positive for CD13 and CD90 largely predominated with respect to CD133, EpCAM and LGR5. CD13+ cells predominated in mixed-IHCCA with respect to mucin-IHCCA, while the opposite was found for CD90+ cells. Mean ± SD of N = 18 independent experiments. * = p< 0.05 vs mucin-IHCCA; & = p< 0.01 vs mixed-IHCCA.

Journal: PLoS ONE

Article Title: Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures

doi: 10.1371/journal.pone.0142124

Figure Lengend Snippet: (A) Immunohistochemical and immunofluorescence analyses of mixed- and mucin-IHCCA primary cultures for Vimentin, α-SMA, E-Cadherin and the “epithelial” cancer stem cell markers CD133+, EpCAM+, LGR5+ and for IL6. A diffuse positivity for mesenchymal markers (Vimentin, α-SMA) and IL6 was observed while E-Cadherin was virtually negative and less than 5% cells where positive for the “epithelial” cancer stem cell markers. Representative experiment of N = 12 independent staining performed in separate primary cultures. (B) Flow cytometry analyses of primary cultures of mixed- and mucin-IHCCA (20–30 passages), labeled with anti-CD13, anti-CD90, anti-EpCAM, anti-CD133, and anti-LGR5 antibodies. Bar graphs and representative plots. Cells positive for CD13 and CD90 largely predominated with respect to CD133, EpCAM and LGR5. CD13+ cells predominated in mixed-IHCCA with respect to mucin-IHCCA, while the opposite was found for CD90+ cells. Mean ± SD of N = 18 independent experiments. * = p< 0.05 vs mucin-IHCCA; & = p< 0.01 vs mixed-IHCCA.

Article Snippet: Cells were rinsed twice with PBS buffer for 2 min, blocked and incubated 1 hour with the following antibodies: Vimentin mouse monoclonal IgG1 (sc-32322, Santa Cruz Biotechnology), α-SMA mouse monoclonal IgG1(M0851, Dako), E-Cadherin mouse monoclonal IgG1 (sc-21791, Santa Cruz Biotechnology), CD326/EpCAM mouse monoclonal IgG1 (sc-59782, Santa Cruz Biotechnology), CD133/PROM1 mouse monoclonal IgG1 (TA309943, Origene), LGR5 rabbit polyclonal IgG (TA301323,Origene), cytokeratin-19 (CK-19) sc-6278 CK-19 mouse monoclonal IgG2a (Santa Cruz Biotechnology), Interleukin 6 (IL6) mouse monoclonal IgG2a (ab9324, Abcam) at room temperature.

Techniques: Immunohistochemical staining, Immunofluorescence, Staining, Flow Cytometry, Labeling

RT-PCR analysis of Vimentin and cancer stem cell surface markers.

Journal: PLoS ONE

Article Title: Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures

doi: 10.1371/journal.pone.0142124

Figure Lengend Snippet: RT-PCR analysis of Vimentin and cancer stem cell surface markers.

Article Snippet: Cells were rinsed twice with PBS buffer for 2 min, blocked and incubated 1 hour with the following antibodies: Vimentin mouse monoclonal IgG1 (sc-32322, Santa Cruz Biotechnology), α-SMA mouse monoclonal IgG1(M0851, Dako), E-Cadherin mouse monoclonal IgG1 (sc-21791, Santa Cruz Biotechnology), CD326/EpCAM mouse monoclonal IgG1 (sc-59782, Santa Cruz Biotechnology), CD133/PROM1 mouse monoclonal IgG1 (TA309943, Origene), LGR5 rabbit polyclonal IgG (TA301323,Origene), cytokeratin-19 (CK-19) sc-6278 CK-19 mouse monoclonal IgG2a (Santa Cruz Biotechnology), Interleukin 6 (IL6) mouse monoclonal IgG2a (ab9324, Abcam) at room temperature.

Techniques:

Figure 2. Dynamic alterations of lung TJ and AJ, HUVEC permeability, and neutrophils after LPS administration in vivo and in vitro. E-cadherin (A, A9), VE-cadherin (B, B9), occludin (C, C0), CD11b (E, E9), and MPO (F, F9) staining and quantification of relative intensity or positive cells in 1 alveoli at 1, 3, 5, and 7 d after administration of LPS (15 mg/kg) or saline; and CD3, CD5, CD19, and CD45 staining (G) at 3 d after LPS treatment are shown. D) Double-labeling images are shown of occludin (red) with E-cadherin or VE-cadherin (green) and superimposition with DAPI (blue). H) Percentage of CD11b-, MPO-, CD3-, CD5-, CD19-, and CD45-positive cells in 1 alveoli. I) Levels of IL-6, IL-8, and TNF-a and MPO activity in the supernatants of human neutrophils at 1, 3, 5, 7, and 9 h after LPS (10 mg/ml) treatment are shown. J) HUVEC monolayer permeability, as reflected by FITC-albumin fluorescence intensity, was analyzed at 1, 3, 5, 7, and 9 h after treatment of LPS alone or LPS + neutrophil supernatants (LPS + S). Values are expressed as the means 6 SE; n = 3 (I, J); n = 10–13 alveoli from 3 mice (A2C9, E9,F9, H). Scale bars: 5 mm (D); 30 mm (A–C. E–G). N.S., no significant difference. **P , 0.01 compared with the control group, ##P , 0.01 compared with LPS group at 1 h.

Journal: The FASEB Journal

Article Title: A self‐organized actomyosin drives multiple intercellular junction disruption and directly promotes neutrophil recruitment in lipopolysaccharide‐induced acute lung injury

doi: 10.1096/fj.201701506rr

Figure Lengend Snippet: Figure 2. Dynamic alterations of lung TJ and AJ, HUVEC permeability, and neutrophils after LPS administration in vivo and in vitro. E-cadherin (A, A9), VE-cadherin (B, B9), occludin (C, C0), CD11b (E, E9), and MPO (F, F9) staining and quantification of relative intensity or positive cells in 1 alveoli at 1, 3, 5, and 7 d after administration of LPS (15 mg/kg) or saline; and CD3, CD5, CD19, and CD45 staining (G) at 3 d after LPS treatment are shown. D) Double-labeling images are shown of occludin (red) with E-cadherin or VE-cadherin (green) and superimposition with DAPI (blue). H) Percentage of CD11b-, MPO-, CD3-, CD5-, CD19-, and CD45-positive cells in 1 alveoli. I) Levels of IL-6, IL-8, and TNF-a and MPO activity in the supernatants of human neutrophils at 1, 3, 5, 7, and 9 h after LPS (10 mg/ml) treatment are shown. J) HUVEC monolayer permeability, as reflected by FITC-albumin fluorescence intensity, was analyzed at 1, 3, 5, 7, and 9 h after treatment of LPS alone or LPS + neutrophil supernatants (LPS + S). Values are expressed as the means 6 SE; n = 3 (I, J); n = 10–13 alveoli from 3 mice (A2C9, E9,F9, H). Scale bars: 5 mm (D); 30 mm (A–C. E–G). N.S., no significant difference. **P , 0.01 compared with the control group, ##P , 0.01 compared with LPS group at 1 h.

Article Snippet: CD3, CD5, and CD45 antibodies were purchased from Proteintech Group (Rosemont, IL, USA).

Techniques: Permeability, In Vivo, In Vitro, Staining, Saline, Labeling, Activity Assay, Control